Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness
- PMID: 37388610
- PMCID: PMC10300666
- DOI: 10.7759/cureus.39624
Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness
Abstract
Age-related macular degeneration (AMD) is a significant cause of blindness globally. With the exponential rise in the aging population, AMD is the third leading cause of visual impairment worldwide. Neovascular AMD (nAMD; Wet AMD) and geographical atrophy (GA, late-stage dry AMD) are the advanced AMD accountable for substantial cases of visual deterioration among the elderly. Our review of the literature depicted that notable risk factors include cigarette smoking, nutritional elements, cardiovascular disorders, and genetic markers, including genes regulating complement, lipid, and angiogenic pathways. Some studies have suggested a relative decline in the proportion of AMD cases in the last two decades attributable to novel diagnostic and therapeutic modalities. Accurate diagnosis is the result of a combination of clinical examination and imaging techniques, including retinal photography, angiography, and optical coherence tomography. The incorporation of dietary antioxidant supplements, explicitly lutein, slows the progression of the disease in advanced stages. The induction of vascular endothelial growth factor (VEGF) inhibitors in the treatment of neovascular AMD, often combined with other modalities, has shown an immensely favorable prognosis. Research to integrate gene therapy and regenerative techniques using stem cells is underway to further mitigate AMD-associated morbidity. It is imperative to establish screening and therapeutic guidelines for AMD to curtail the future social and financial burden and improve the diminishing quality of life among the elderly.
Keywords: age related macular degeneration; anti-vegf; drusen; neovascular age-related macular degeneration; oct (optical coherence tomography).
Copyright © 2023, Chaudhuri et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
Age-related macular degeneration.Lancet. 2012 May 5;379(9827):1728-38. doi: 10.1016/S0140-6736(12)60282-7. Lancet. 2012. PMID: 22559899 Review.
-
Recent Advances in Imaging Macular Atrophy for Late-Stage Age-Related Macular Degeneration.Diagnostics (Basel). 2023 Dec 10;13(24):3635. doi: 10.3390/diagnostics13243635. Diagnostics (Basel). 2023. PMID: 38132220 Free PMC article. Review.
-
Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.Clin Ophthalmol. 2015 Nov 20;9:2159-74. doi: 10.2147/OPTH.S92359. eCollection 2015. Clin Ophthalmol. 2015. PMID: 26640366 Free PMC article. Review.
-
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.Biomolecules. 2022 Nov 3;12(11):1629. doi: 10.3390/biom12111629. Biomolecules. 2022. PMID: 36358978 Free PMC article. Review.
-
Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors.Oxid Med Cell Longev. 2020 Dec 8;2020:4984927. doi: 10.1155/2020/4984927. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33520083 Free PMC article. Review.
Cited by
-
Potential Use of Plasma Rich in Growth Factors in Age-Related Macular Degeneration: Evidence from a Mouse Model.Medicina (Kaunas). 2024 Dec 10;60(12):2036. doi: 10.3390/medicina60122036. Medicina (Kaunas). 2024. PMID: 39768916 Free PMC article.
-
Looking beyond the eyes of the patient: The importance of effective communication in the treatment of age-related macular degeneration.Acta Ophthalmol. 2025 Mar;103(2):205-214. doi: 10.1111/aos.16777. Epub 2024 Oct 25. Acta Ophthalmol. 2025. PMID: 39450444 Free PMC article.
-
Role of Oxidative Stress and Inflammation in Age Related Macular Degeneration: Insights into the Retinal Pigment Epithelium (RPE).Int J Mol Sci. 2025 Apr 8;26(8):3463. doi: 10.3390/ijms26083463. Int J Mol Sci. 2025. PMID: 40331961 Free PMC article. Review.
-
Validation of the Chinese version of the financial toxicity scale in patients with wet age-related macular degeneration.J Patient Rep Outcomes. 2025 Jun 16;9(1):69. doi: 10.1186/s41687-025-00909-x. J Patient Rep Outcomes. 2025. PMID: 40522574 Free PMC article.
-
Phlorizin Protects Against Oxidative Stress and Inflammation in Age-Related Macular Degeneration Model.Biomolecules. 2025 Apr 3;15(4):523. doi: 10.3390/biom15040523. Biomolecules. 2025. PMID: 40305267 Free PMC article.
References
-
- Review: antioxidant protection of the ageing macula. Gerster H. Age Ageing. 1991;20:60–69. - PubMed
-
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Lancet Glob Health. 2014;2:106–116. - PubMed
-
- Age-related macular degeneration. Thomas CJ, Mirza RG, Gill MK. Med Clin North Am. 2021;105:473–491. - PubMed
Publication types
LinkOut - more resources
Full Text Sources